Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
53 studies found for:    Open Studies | "Hemorrhagic Fevers, Viral"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Hemorrhagic Fevers, Viral" (53 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Not yet recruiting Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever
Condition: Viral Hemorrhagic Fever
Intervention: Drug: Ribavirin
2 Recruiting Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever
Condition: Hemorrhagic Fever With Renal Syndrome
Interventions: Biological: HTNV/PUUV DNA vaccine;   Biological: Placebo
3 Recruiting Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi
Condition: Ebola Hemorrhagic Fever
Intervention: Procedure: blood sampling collection
4 Recruiting Open Study of the Duration of Immunity After Vaccination With GamEvac
Condition: Hemorrhagic Fever, Ebola
Intervention: Procedure: blood sampling collection
5 Recruiting Safety, Tolerability and Immunogenicity Study of 2 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: Placebo
6 Recruiting Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo
7 Recruiting Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: Placebo
8 Recruiting Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever
Interventions: Biological: CYD Dengue Vaccine (5 dose formulation);   Biological: Placebo, NaCl 0.9%
9 Recruiting Diagnostic of Puumala Virus Infection in France
Conditions: Nephropathia Epidemica;   Hemorrhagic Fever With Renal Syndrome
Intervention:
10 Recruiting Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever;   Human Papillomavirus Disease
Interventions: Biological: CYD Dengue Vaccine;   Biological: Human Papillomavirus Bivalent [Types16 and 18] Vaccine, Recombinant.;   Biological: Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant.
11 Not yet recruiting Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever;   Human Immunodeficiency Virus
Interventions: Biological: CYD Dengue Vaccine;   Biological: Placebo (NaCl 0.9%) vaccine group
12 Recruiting GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen
Condition: Persistent Ebola Virus
Interventions: Drug: GS-5734;   Other: Placebo Comparator
13 Recruiting Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen
Condition: Ebola Virus Survivor
Intervention: Drug: Favipiravir
14 Recruiting A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo
Conditions: Ebola;   Ebola Zaire
Interventions: Biological: cAd3-EBO Z at 1 x 10^10 vp;   Biological: cAd3-EBO Z at 2.5 x 10^10 vp;   Biological: cAd3-EBO Z at 5 x 10^10 vp;   Biological: 4.4x10^8 TCID50s MVA-BN® Filo;   Biological: 2.2x10^8 TCID50s MVA-BN® Filo;   Biological: 4.4 x 10^7 TCID50s MVA-BN® Filo
15 Not yet recruiting Partnership for Research on Ebola VACcinations
Condition: Ebola Virus Disease
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: rVSVΔG-ZEBOV-GP;   Biological: Placebo;   Biological: rVSV boost
16 Recruiting Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up
Condition: Ebola Virus Disease
Intervention:
17 Not yet recruiting Multiple Treatments for Ebola Virus Disease (EVD)
Condition: Ebola Virus Disease
Interventions: Drug: Azithromycin;   Drug: Sunitinib and Erlotinib;   Drug: Atorvastatin and Irbesartan;   Other: IV fluids and laboratory testing
18 Recruiting Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment
Condition: Ebola Virus Disease
Intervention: Procedure: Convalescent Plasma Treatment
19 Not yet recruiting Repeatability and Reproducibility of the ArcScan Insight 100 VHF Digital Ultrasound
Conditions: Corneal Thickness Measurement;   Epithelial Thickness Measurement;   Anterior Eye Segment Measurements
Intervention: Device: ArcScan Insight 100 very high-frequency digital ultrasound
20 Not yet recruiting MVA-BN®-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers
Conditions: Marburg Disease;   Ebola Disease
Interventions: Biological: MVA Multi-Filo Ebola Vaccine;   Biological: Ad26 Zaire Ebola Vaccine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.